Novel Vaccines for Infectious Pathogens
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 40523
Special Issue Editors
Interests: immunology; vaccines; host-pathogen interactions; zoonotic infectious diseases
Special Issue Information
Dear Colleagues,
Vaccines are one of the most important life-saving public health tools. This is truly exemplified in the context of the ongoing COVID-19 pandemic. COVID-19 has been a real wake-up call for researchers worldwide that they must be vigilant and prepared to mitigate the next pandemic, emerging or re-emerging infectious disease, or zoonotic infectious disease of food for animals/humans. Zoonotic infectious diseases of food for animals/humans caused by Swine influenza A viruses; avian influenza A viruses, such as highly pathogenic avian influenza in commercial and backyard flocks; or Salmonella in poultry are of significant public health and economic importance. According to an estimate by the centers for disease control and prevention (CDC), from 2009 to 2018, influenza A H1N1 pdm09 has caused at least 100.5 million illnesses, 936,000 hospitalizations, and 75,000 deaths in the United States.
Hence, novel vaccines against zoonotic infectious diseases of food for animals/humans are essential.
In this Special Issue, original research articles and literature or perspective reviews are welcome. Research areas may include, but are not limited to, the following: novel vaccines based on a variety of platforms/delivery/mechanism of action (innate immunity-based, trained immunity-based, CRISPR-based, AI-based, immunoinformatics-based, multi-omics-based, nanotechnology-based, mucosal nanovaccines, nucleic acid-based, protein subunit-based, cytotoxic T-cell-based, peptide epitope-based vaccines, nanoemulsion-based, plant-based, dendritic cell-based, vector-based, mRNA-based) against zoonotic and emerging infectious diseases of food for animals and humans, caused by viruses, such as swine influenza A viruses, avian influenza A viruses, and multi drug-resistant zoonotic pathogens, such as methicillin-resistant Staphylococcus aureaus (MRSA), Pseudomonas aeruginosa, and carbapenem-resistant enterobacterales (CRE), all of which are welcome.
We look forward to receiving your contributions.
Dr. Veerupaxagouda Patil
Dr. Dhruv Desai
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mucosal nanovaccines
- zoonotic
- infectious diseases
- food animals
- epitope based
- trained immunity based
- novel platform
- multi-drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.